Pacer Advisors, Inc. Sage Therapeutics, Inc. Transaction History

Pacer Advisors, Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$10.58 - $17.9 $11,902 - $20,137	-1,125 Reduced 61.61%	701 $7,000
Q1 2024 May 10, 2024	BUY	$18.62 - $26.95 $34,000 - $49,210	1,826 New	1,826 $34,000
Q2 2021 Jul 21, 2021	SELL	$54.88 - $79.29 $54,386 - $78,576	-991 Closed	0 $0
Q1 2021 Apr 05, 2021	SELL	$70.65 - $96.76 $67,965 - $93,083	-962 Reduced 49.26%	991 $74,000
Q4 2020 Jan 20, 2021	SELL	$58.41 - $89.06 $55,489 - $84,607	-950 Reduced 32.72%	1,953 $169,000
Q3 2020 Oct 19, 2020	BUY	$41.13 - $62.45 $119,400 - $181,292	2,903 New	2,903 $177,000
Q4 2018 Feb 13, 2019	SELL	$81.94 - $139.71 $135,446 - $230,940	-1,653 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$138.11 - $169.04 $228,295 - $279,423	1,653 New	1,653 $233,000
Q1 2018 May 14, 2018	SELL	$152.15 - $192.33 $125,523 - $158,672	-825 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$60.72 - $167.34 $50,094 - $138,055	825	825 $136,000

198

46.5M

402K

209K

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $323M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

Get notified when there are updates to the investment portfolio of Pacer Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on Pacer Advisors, Inc. with notifications on news.